{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031246","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.798500+00:00","generated_at":"2026-06-22T00:24:45.333150+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProPhase Labs Q3 net revenue $24.2M (+155% YoY), net income $1.0M vs loss, adj. EBITDA $6.3M record","bullets":["Q3 2022 net revenue $24.2M, up 155% from $9.5M in Q3 2021; net income $1.0M ($0.06 EPS) vs net loss $4.0M ($0.26 loss).","Adjusted EBITDA $6.3M (record for Q3) versus adjusted EBITDA loss of $1.3M in the prior-year quarter.","Cash, cash equivalents & restricted cash $22.8M at Sep 30, 2022 vs $8.7M at Dec 31, 2021; working capital $53.6M.","Signed MOU with G42 Healthcare for genomic sequencing/AI; entered two-year collaborative agreement with Dana-Farber for Linebacker-1 cancer co-therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031246","json":"https://secwatch.observer/filing/0001493152-22-031246.json","markdown":"https://secwatch.observer/filing/0001493152-22-031246.md","text":"https://secwatch.observer/filing/0001493152-22-031246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/0001493152-22-031246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:24:45.333150+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ef5a9b5122bfde70c960a2df061a6325c96eedbe","claim":"ProPhase Labs, Inc. reported the third quarter ended September 30, 2022 results: revenue $24.2 million, net income $1.0 million, or $0.06 per share, EPS $0.06 per share.","evidence_excerpt":"Current Report on Form 8-K. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 ProPhase Labs Announces Record Third Quarter 2022 Financial Results Q3 2022 Net Revenues of $24.2 Million (a Q3 record); Up 155% Year-over-Year Q3 2022 Net Income of $1.0 Million versus a loss in Q3 2021 Q3 2022 adjusted EBITDA of $6.3 million (a Q3 record) versus a loss in Q3 2021","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315222031246/0001493152-22-031246-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$24.2 million"},{"label":"Net income","value":"$1.0 million, or $0.06 per share"},{"label":"EPS","value":"$0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}